smallpox
declar
erad
howev
recent
need
agent
effect
poxviru
infect
emerg
paper
report
origin
find
two
redoxmodul
agent
ethacryn
acid
ea
la
inhibit
growth
vaccinia
viru
vacv
vitro
effect
ea
la
compar
dtt
ascorb
acid
agent
increas
vacv
growth
hela
g
cell
inhibitori
effect
ea
la
growth
vacv
confirm
sever
cell
line
differ
embryon
origin
epitheli
cell
fibroblast
macrophag
tlymphocyt
final
analyz
mechan
action
two
agent
decreas
express
vacv
late
gene
demonstr
western
blot
analysi
activ
luciferas
express
control
differ
vacv
promot
contrast
inhibit
viru
entri
cell
express
vacv
earli
gene
vacv
dna
synthesi
result
suggest
new
direct
develop
drug
effect
poxviru
infect
vaccinia
virus
vacv
variou
strain
use
past
widespread
vaccin
smallpox
lead
erad
lifethreaten
diseas
world
health
organ
smallpox
erad
program
declar
diseas
erad
vaccin
gener
popul
stop
along
rise
concern
smallpox
misus
bioterrorist
attack
certain
countri
reintroduc
vaccin
program
among
select
group
popul
reconsid
vaccin
gener
popul
howev
old
vaccin
avail
new
york
citi
board
health
strain
vaccinia
viru
dryvax
wyeth
laboratori
probabl
also
new
vaccin
base
viru
strain
prepar
tissu
cultur
eg
acambi
reveal
substanti
risk
postvaccin
complic
artenstein
sever
complic
describ
erad
campaign
includ
progress
vaccinia
vaccinia
necrosum
postvaccin
enceph
eczema
vaccinatum
aragon
et
al
new
complic
myopericard
describ
base
recent
vaccin
militari
personnel
old
dryvax
vaccin
us
depart
defens
ar
et
al
also
occur
trial
new
tissu
culturebas
vaccin
artenstein
correspond
author
tel
fax
email
address
zmelk
z
melkova
author
contribut
equal
work
addit
need
effici
therapi
vaccinia
virusrel
postvaccin
complic
variola
infect
risk
infect
human
monkeypox
viru
viru
endem
africa
case
also
report
unit
state
ligon
reed
et
al
current
therapeut
possibl
poxviru
infect
rather
limit
vaccinia
immun
globulin
vig
use
passiv
immun
provid
immedi
week
last
protect
infect
well
treatment
postvaccin
complic
howev
effect
never
assess
properli
control
trial
bray
wright
drug
current
allow
use
us
food
drug
administr
fda
treatment
certain
reaction
smallpox
vaccin
cidofovir
cdv
nucleosid
analogu
origin
approv
treatment
cmv
infect
immunocompromis
individu
de
clercq
de
clercq
disadvantag
compound
intraven
administr
nephrotox
safrin
et
al
etherlipid
analogu
cdv
reveal
good
oral
bioavail
low
toxic
similar
antipoxviru
effici
cdv
parker
et
al
compound
current
evalu
clinic
trial
http
wwwchimerixinccompdf
news
chimerix
anoth
drug
inhibit
late
step
vacv
morphogenesi
egress
cell
yang
et
al
also
evalu
clinic
trial
http
wwwsigacom
experiment
drug
permit
use
singl
case
eczema
vaccinatum
togeth
vig
cidofovir
kaiser
addit
thiosemicarbazon
deriv
use
past
antipoxviru
prophylaxi
well
treatment
effect
individu
deriv
never
properli
assess
placebocontrol
human
trial
pirrung
et
al
smee
sidwel
recent
studi
mice
howev
suggest
neither
ibt
deriv
marboran
may
use
therapi
poxviru
infect
effect
reduc
mortal
mice
infect
system
vacv
cowpox
viru
reduc
replic
either
viru
clinic
ill
mice
infect
cutan
quenel
et
al
paper
report
new
find
ethacryn
acid
inhibit
growth
vaccinia
viru
vitro
ethacryn
acid
ea
well
known
clinic
use
thiolreact
diuret
agent
na
k
cl
cotransport
system
inhibitor
avail
variou
trade
name
eg
edecrin
edecril
reomax
griffith
simmon
koechel
rankin
also
use
decreas
intraocular
pressur
glaucoma
melam
et
al
final
known
inhibit
glutathionestransferas
piclass
gst
thu
deplet
cytosol
mitochondri
store
gsh
serv
experiment
prooxid
meredith
reed
inhibit
gst
ea
clinic
employ
potenti
effect
anticanc
drug
decreas
conjug
elimin
organ
gate
tew
acid
la
thiolcontain
redoxcycl
agent
lipoamid
serv
cofactor
pyruv
dehydrogenas
multienzym
complex
catalyz
oxid
decarboxyl
acid
addit
act
antioxid
involv
free
radic
quench
antioxid
recycl
metal
chelat
shown
effect
variou
experiment
clinic
studi
focus
therapi
alzheim
neurodegen
diseas
diabet
myocardi
cerebr
ischemiareperfus
injuri
holmquist
et
al
packer
et
al
la
use
food
addit
avail
variou
trade
name
eg
alpha
lipoic
acid
heparlipon
thioctsan
also
propos
amelior
hivinduc
redoxstress
organ
jariwalla
et
al
describ
ea
la
inhibit
growth
vaccinia
viru
vitro
sever
cell
type
dosedepend
manner
contrast
redoxmodul
agent
dtt
ascorb
acid
reveal
inhibitori
effect
similar
concentr
contrari
promot
vacv
growth
effect
concentr
ea
found
low
micromolar
rang
la
high
micromolar
rang
mechan
action
seem
howev
similar
compoundsthey
appear
inhibit
express
vacv
late
gene
result
decreas
level
infecti
viru
progeni
two
compound
seem
affect
either
vacv
entri
cell
viral
dna
synthesi
media
growth
supplement
purchas
invitrogen
corpor
carlsbad
ca
paa
laboratori
gmbh
pasch
austria
lascorb
acid
dithiothreitol
dtt
ethacryn
acid
acid
cytosin
arabinosid
arac
methylthiazolyldiphenyltetrazolium
bromid
mtt
atp
purchas
sigma
co
st
loui
mo
mous
recombin
r
system
minneapoli
mn
luciferin
purchas
promega
madison
wi
enzym
primer
probe
chemic
realtim
pcr
purchas
appli
biosystem
foster
citi
ca
chemic
supplement
purchas
sigma
co
unless
otherwis
specifi
stock
solut
redoxmodul
antivir
agent
prepar
follow
water
dtt
water
mm
ascorb
acid
water
mm
ea
pb
mm
la
ethanol
mgml
arac
water
aliquot
stock
solut
kept
c
dilut
shortli
experi
human
cervic
carcinomaderiv
hela
g
et
al
scherer
et
al
african
green
monkey
kidneyderiv
hrubi
et
al
esteban
cell
line
grown
dulbecco
modifi
eagl
medium
dmem
glucos
gl
supplement
heatinactiv
neonat
calf
serum
nc
ncsdmem
antibiot
penicilin
ul
streptomycin
mgl
mous
fibroblast
lai
et
al
sanford
et
al
mous
monocytemacrophag
esteban
unkeless
et
al
cell
line
grown
dmem
glucos
gl
supplement
heatinactiv
fetal
bovin
serum
fbsdmem
antibiot
macrophag
also
pretreat
uml
r
system
h
infect
human
tcell
deriv
jurkat
cell
line
clone
atcc
grown
rpmi
supplement
heatinactiv
fetal
bovin
serum
fbsrpmi
antibiot
mm
hepe
ph
mm
glutamin
cell
maintain
c
co
atmospher
humid
virus
use
includ
wildtyp
wt
vacv
strain
western
reserv
wr
atcc
et
al
sever
vacv
recombin
rvacv
express
report
gene
recombin
prepar
homolog
recombin
wt
vacv
strain
wr
tk
gene
reveal
similar
growth
properti
vitro
rvacv
express
luciferas
either
control
vacv
earlyl
promot
luc
el
control
vacv
late
promot
luc
l
describ
previous
rodriguez
et
al
rodriguez
smith
rvacv
express
chloramphenicol
acetyltransferas
gene
control
iptginduc
vacv
late
promot
gener
kindli
provid
dr
sb
lee
lee
et
al
virus
propag
cell
line
dmem
supplement
nc
antibiot
ncsdmem
viru
titer
determin
serial
dilut
plaqu
assay
cell
viru
yield
determin
infect
cell
collect
directli
cultur
medium
lyse
two
cycl
freezingthaw
sonic
viru
yield
determin
dilut
dmem
plaqu
assay
cell
briefli
cell
plate
plate
densiti
cell
per
well
ncsdmem
h
later
l
dilut
allow
adsorb
cell
h
shake
everi
min
remov
viru
inocula
cell
supplement
ncsdmem
incub
h
cell
fix
paraformaldehyd
pb
stain
crystal
violet
pb
addit
ethanol
viru
plaqu
count
viru
yield
express
pfuml
plaqu
reduct
assay
perform
use
similar
protocol
minor
modif
briefli
cell
infect
approxim
pfu
crude
stock
wt
vacv
rvacv
lucl
fix
stain
hpi
experi
adher
cell
plate
fresh
cultur
medium
h
experi
plate
densiti
cell
per
well
respect
suspens
cell
dilut
fresh
cultur
medium
h
experi
infect
cell
wash
serumfre
medium
viru
inocula
ad
serumfre
medium
multipl
infect
moi
allow
adsorb
h
shake
everi
min
crude
stock
virus
use
infect
hela
g
cell
line
infect
macrophag
tcell
line
virus
purifi
sucros
gradient
joklik
remov
viru
inocula
cell
supplement
ncsdmem
hela
g
fbsdmem
fbsrpmi
jurkat
appropri
concentr
test
compound
vehiculum
h
infect
hpi
time
indic
experi
cell
collect
process
analyz
serial
dilut
plaqu
assay
measur
luciferas
activ
western
blot
analysi
realtim
pcr
inhibitori
concentr
compound
express
ic
ic
concentr
test
compound
reduc
viru
growth
luciferas
activ
mocktreat
control
respect
valu
calcul
linear
exponenti
regress
character
depend
viru
yield
luciferas
activ
concentr
test
compound
hela
g
cell
plate
plate
densiti
cell
per
well
ncsdmem
h
later
cell
infect
crude
stock
rvacv
luc
l
rodriguez
et
al
rodriguez
smith
describ
ea
la
vehicula
includ
inoculum
whole
incub
period
ad
variou
hpi
hpi
cell
collect
viru
growth
character
luciferas
activ
collect
cell
wash
twice
pb
process
accord
publish
protocol
minor
modif
brasier
et
al
rodriguez
et
al
briefli
cell
lyse
l
luciferas
extract
buffer
contain
mm
glycylglycin
ph
triton
mm
mgso
mm
egta
mm
dtt
proteas
inhibitor
complet
roch
basel
switzerland
luciferas
activ
determin
mm
atp
ph
mm
luciferin
mm
hepe
ph
mm
nacl
mm
edta
mm
mgcl
polyethylen
glycol
use
luminomet
microlit
tlx
dynatech
laboratori
cell
collect
lyse
laemmli
reduc
sampl
buffer
boil
analyz
sdspage
western
blot
previous
describ
ausubel
et
al
vacv
polypeptid
detect
rabbit
antiserum
vacv
dilut
antiserum
rais
immun
live
vacv
gener
kindli
provid
dr
jr
rodriguez
fig
rodriguez
et
al
inactiv
purifi
vacv
prepar
sevaimuno
praha
czech
republ
fig
peroxidaseconjug
goat
antirabbit
igg
dilut
mp
biomed
cappel
solon
oh
chromogen
substrat
luciferas
detect
rabbit
polyclon
antibodi
dilut
santa
cruz
biotechnolog
santa
cruz
ca
peroxidaseconjug
goat
antirabbit
igg
dilut
mp
biomed
cappel
solon
oh
chemiluminesc
west
femto
thermo
fisher
scientificpierc
rockford
il
cell
collect
pipet
wash
twice
pb
total
dna
isol
use
treatment
proteinas
k
phenolchloroform
extract
ea
sampl
ausubel
et
al
use
pcr
lysi
buffer
contain
proteinas
k
la
sampl
schmidtmayerova
et
al
vacv
dna
quantifi
realtim
pcr
use
appli
biosystem
realtim
pcr
system
primer
probe
design
appli
biosystem
custom
taqman
gene
express
assay
set
primer
probe
design
endtermin
part
vaccinia
viru
genom
bp
forward
primer
bp
cgtatcacactattgagacagaaaaagaaga
revers
primer
bp
gacactatattccggtttgcaaaaca
fam
probe
bp
tcgcgagaggtaactttttgtga
strain
western
reserv
genbank
access
absolut
quantif
vacv
growth
standard
contain
amplif
site
clone
pcr
gener
generibiotech
hradec
kralov
czech
republ
gener
calibr
curv
standard
dilut
copiesreact
ng
total
dna
subject
realtim
pcr
reaction
mixtur
consist
taqman
univers
pcr
master
mix
amperas
ung
appli
biosystem
foster
citi
ca
assay
mix
contain
set
primer
label
probe
custom
taqman
gene
express
assay
appli
biosystem
foster
citi
ca
reaction
carri
final
volum
l
univers
thermal
cycl
condit
use
initi
denatur
min
cycl
consist
denatur
annealingextens
min
sampl
includ
standard
nontempl
control
run
duplic
data
analyz
sequenc
detect
softwar
version
appli
biosystem
foster
citi
ca
cytotox
test
compound
character
inhibit
cell
growth
use
protocol
adapt
accord
kit
sigma
co
st
loui
mo
briefli
adher
cell
plate
plate
densiti
ml
well
cultur
medium
h
later
cell
suppli
fresh
medium
contain
increas
concentr
individu
compound
suspens
cell
dilut
fresh
cultur
medium
h
later
plate
plate
densiti
ml
well
cultur
medium
contain
increas
concentr
individu
compound
day
incub
cell
growth
viabil
character
activ
mitochondri
dehydrogenas
use
mtt
assay
convers
mtt
formazan
determin
photometr
nm
dissolv
product
acidifi
isopropanol
cytotox
concentr
express
cc
concentr
test
compound
reduc
cell
growth
compar
vehiculumtr
control
result
present
mean
sd
standard
deviat
statist
differ
within
group
evalu
use
anova
statist
differ
mocktreat
control
differ
concentr
compound
two
distinct
group
determin
use
twosampl
twotail
student
ttest
tabl
antivir
cytotox
effect
ethacryn
acid
vaccinia
viru
differ
cell
line
cell
differ
origin
infect
recombin
vacv
express
luciferas
moi
remov
viru
inoculum
cell
treat
indic
concentr
ethacryn
acid
macrophag
also
pretreat
uml
hpi
cell
collect
viru
yield
luciferas
activ
determin
inhibitori
concentr
compound
express
concentr
requir
inhibit
viru
growth
character
luciferas
activ
viru
titer
respect
cytotox
experi
cell
treat
increas
concentr
test
compound
day
incub
cytotox
character
use
mtt
assay
concentr
test
compound
reduc
activ
mitochondri
dehydrogenas
compar
vehiculumtr
control
result
repres
mean
experi
perform
duplic
sd
lipoic
acid
luc
titer
luc
titer
observ
two
redoxmodul
agent
ea
la
inhibit
growth
vacv
vitro
therefor
first
compar
effect
differ
redoxmodul
agent
growth
vacv
character
activ
luciferas
express
rvacv
hela
g
cell
infect
rvacv
express
luciferas
control
vacv
late
promot
luc
l
result
indic
test
concentr
dithiothreitol
lascorb
acid
significantli
increas
luciferas
activ
express
rvacv
concentr
agent
increas
luciferas
activ
mocktreat
control
p
contrast
la
ea
reveal
statist
signific
inhibitori
effect
p
luciferas
activ
decreas
mocktreat
control
presenc
la
presenc
mm
la
inhibitori
effect
ea
strongerluciferas
activ
decreas
presenc
ea
respect
almost
complet
abolish
presenc
ea
conclus
ea
la
reveal
inhibitori
effect
vacv
growth
agent
dithiothreitol
lascorb
acid
promot
base
find
describ
decid
character
effect
ea
la
vacv
growth
cell
line
differ
originin
human
monkey
epitheli
cell
line
hela
g
respect
mous
fibroblast
mous
macrophag
untreat
pretreat
interferon
tabl
gener
valu
ic
ic
lower
rvacv
wt
vacv
valu
ic
lower
calcul
viru
titer
luciferas
activ
rvacv
wt
vacv
valu
ic
respect
ic
respect
lowest
hela
g
cell
treat
ea
rest
cell
valu
ic
ea
rang
virus
case
la
valu
ic
rang
rvacv
wt
vacv
consequ
test
cytotox
growth
inhibitori
properti
ea
la
activ
divid
cell
determin
activ
mitochondri
dehydrogenas
use
mtt
assay
indic
tabl
ea
affect
growth
viabil
epitheli
cell
hela
g
fibroblast
rel
modestli
contrast
macrophag
especi
jurkat
tcell
inhibit
compound
result
low
select
indic
si
analog
la
found
inhibit
growth
hela
g
cell
mm
contrari
promot
cell
growth
inhibit
growth
macrophag
rel
low
concentr
cc
start
inhibit
jurkat
cell
mm
highest
concentr
test
hand
neither
ea
la
induc
obviou
cytotox
condit
antivir
assay
ie
higher
cell
densiti
serum
h
incub
mm
respect
data
shown
also
see
fig
evalu
effect
ea
la
vacv
growth
plaqu
reduct
assay
perform
sinc
vacv
gener
viru
plaqu
hela
g
cell
cell
use
plate
plate
infect
pfu
wt
vacv
rvacv
presenc
increas
dose
ea
la
h
shown
fig
ea
reduc
number
plaqu
form
wt
vacv
cell
size
remain
almost
unchang
contrast
la
reduc
size
plaqu
without
affect
number
similar
result
obtain
also
rvacv
luc
l
shown
conclus
ea
la
reveal
inhibitori
effect
vacv
growth
luciferas
activ
cell
line
test
base
result
mtt
assay
compound
found
rel
nontox
epitheli
fibroblast
cell
line
si
indic
ea
promot
growth
la
reveal
inhibitori
effect
macrophag
tcell
line
hpi
cell
collect
lyse
luciferas
activ
determin
cell
lysat
ethacryn
acid
graph
repres
mean
independ
experi
perform
duplic
sd
signific
differ
luc
el
luc
l
group
p
twosampl
ttest
b
ethacryn
acid
arac
graph
repres
mean
independ
experi
perform
duplic
sd
signific
differ
luc
el
luc
l
group
p
twosampl
ttest
c
acid
graph
repres
mean
independ
experi
perform
duplic
sd
signific
differ
luc
el
luc
l
group
p
twosampl
ttest
acid
ara
c
graph
repres
mean
independ
experi
perform
duplic
sd
signific
differ
luc
el
luc
l
group
p
twosampl
ttest
possibl
effect
ea
la
vacv
entri
cell
test
hela
g
cell
cell
pretreat
mocktreat
h
infect
individu
agent
appropri
concentr
agent
vehicula
includ
also
viru
inoculum
agent
ad
also
cultur
medium
remov
inoculum
ie
h
infect
hpi
present
whole
incub
period
activ
luciferas
viru
titer
determin
howev
pretreat
cell
ea
la
found
caus
differ
comparison
sampl
treat
hpi
data
shown
consequ
want
character
step
vacv
growth
cycl
inhibit
ea
la
vacv
growth
cycl
sequenti
process
success
accomplish
one
step
prerequisit
next
one
schramm
locker
thu
express
vacv
late
gene
govern
vacv
late
promot
occur
replic
vacv
dna
consequ
recombin
vacv
express
luciferas
control
two
differ
promot
earlyl
luc
el
late
luc
l
combin
inhibit
vacv
dna
synthesi
cytosin
arabinosid
arac
use
distinguish
inhibitori
effect
occur
dna
synthesi
hela
g
cell
infect
luc
el
luc
l
absenc
presenc
arac
inhibitor
dna
polymeras
treat
indic
concentr
ea
la
concentr
arac
use
gml
experiment
determin
inhibit
vacv
growth
induc
death
host
cell
hpi
cell
collect
activ
luciferas
determin
agreement
previou
experi
ea
la
reveal
dosedepend
inhibitori
effect
activ
luc
el
luc
l
absenc
arac
fig
c
presenc
arac
activ
luciferas
express
luc
l
decreas
approxim
less
mocktreat
control
grown
absenc
arac
ie
level
close
background
neither
ea
la
affect
result
fig
respect
contrast
activ
luciferas
express
luc
el
presenc
arac
decreas
less
control
due
persist
express
luciferas
govern
earli
portion
promot
differ
concentr
neither
ea
la
decreas
measur
activ
luciferas
fig
respect
suggest
neither
ea
la
affect
vacv
earli
gene
express
addit
analyz
protein
level
luciferas
sampl
use
determin
luciferas
activ
western
blot
analysi
shown
fig
ea
la
caus
gradual
decreas
level
luciferas
express
either
luc
el
luc
l
absenc
arac
signal
could
detect
presenc
arac
result
reflect
differ
sensit
assay
determin
activ
luciferas
western
blot
analysi
next
analyz
overal
level
vacv
protein
hela
g
cell
infect
differ
recombin
vacv
western
blot
shown
fig
ea
seem
decreas
protein
level
two
differ
recombin
vacv
ea
induc
littl
decreas
ea
almost
complet
inhibit
vacv
protein
express
similarli
la
induc
major
chang
protein
level
two
distinct
recombin
vacv
lower
concentr
highest
concentr
use
mm
decreas
protein
express
slightli
fig
overal
pattern
vacv
protein
express
seem
qualit
compar
sampl
resembl
pattern
vacv
late
protein
express
mocktreat
control
also
note
concentr
ea
la
found
inhibit
vacv
growth
hela
g
cell
previou
experi
seem
consider
affect
vacv
protein
level
thu
inhibitori
effect
ea
la
seem
affect
vacv
late
gene
express
sinc
level
report
gene
luciferas
express
control
vacv
late
promot
well
overal
level
vacv
late
protein
found
decreas
presenc
ea
la
inhibit
vacv
growth
mediat
ea
la
like
occur
level
dna
replic
express
vacv
late
protein
analyz
effect
ea
la
vacv
dna
synthesi
quantifi
number
copi
vacv
genom
dna
time
cours
use
realtim
pcr
howev
absolut
quantif
use
extern
standard
calibr
curv
indic
level
vacv
genom
dna
chang
fig
thu
two
agent
seem
inhibit
vacv
late
gene
express
analyz
effect
ea
la
distinct
stage
vaccinia
viru
growth
cycl
time
addit
assay
perform
hela
g
cell
infect
rvacv
luc
l
express
luciferas
occur
dna
synthesi
two
compound
ad
indic
time
postinfect
hpi
cell
collect
lyse
activ
luciferas
determin
shown
fig
addit
ea
time
test
significantli
decreas
activ
luciferas
inhibitori
effect
smaller
ea
ad
hpi
addit
la
significantli
decreas
activ
luciferas
ad
hpi
ie
time
begin
vacv
dna
synthesi
smaller
signific
inhibit
could
observ
also
la
ad
hpi
time
vacv
dna
synthesi
essenti
complet
indic
realtim
pcr
supplementari
data
fig
effect
time
addit
ethacryn
acid
vacv
growth
character
activ
luciferas
total
hela
g
cell
infect
recombin
vacv
luc
l
moi
ethacryn
acid
acid
vehicula
ad
indic
hpi
hpi
cell
collect
lyse
luciferas
activ
determin
graph
repres
mean
two
independ
experi
perform
duplic
sd
signific
differ
indic
concentr
ea
la
mocktreat
control
p
twosampl
ttest
fig
signific
inhibit
observ
la
ad
hpi
result
compat
previou
conclus
ea
la
seem
inhibit
vacv
late
gene
express
paper
report
new
find
ethacryn
acid
reveal
inhibitori
effect
growth
vaccinia
viru
sever
cell
line
agent
seem
inhibit
vacv
stage
growth
cycl
ie
level
express
late
gene
ea
found
effect
low
micromolar
rang
la
effect
high
micromolar
rang
first
compar
inhibitori
properti
ea
la
redoxmodul
agent
dtt
ascorb
acid
contrast
ea
la
none
agent
inhibit
vacv
growth
hela
g
cell
character
activ
report
luciferas
express
rvacv
sinc
dtt
prototyp
reduc
agent
ascorb
acid
act
predominantli
antioxid
ea
act
prooxid
seem
difficult
find
common
denomin
ea
la
might
help
suggest
mode
action
nevertheless
assum
ea
la
affect
specif
thioldepend
function
vacv
growth
cycl
possibl
imagin
two
agent
might
interfer
disulfid
bond
format
andor
exchang
redox
cycl
thioredoxin
glutaredoxin
similar
compound
differ
effect
concentr
ea
la
may
reflect
mode
modif
thiol
moieti
ea
alkyl
agent
bow
gupta
han
et
al
could
irrevers
bind
essenti
cystein
residu
contrast
action
la
may
revers
due
redox
cycl
packer
et
al
altern
possibl
suggest
net
effect
ea
la
would
prooxid
ea
inhibit
gst
thu
inhibit
regener
gsh
pool
contrast
la
promot
regener
gsh
howev
dihydrolipo
acid
dhla
suppos
form
quickli
la
insid
cell
suggest
releas
iron
storag
protein
ferritin
reduc
fe
fe
fe
initi
lipid
peroxid
consequ
decreas
gsh
level
packer
et
al
case
effect
ea
la
vacv
late
gene
express
might
also
indirect
possibl
action
cascad
event
distinct
step
evid
task
fulfil
dtt
ascorb
acid
compound
favor
reduc
condit
contrari
compound
increas
vacv
growth
suggest
differ
redox
condit
differ
influenc
vacv
growth
effect
might
relat
cytoplasm
redox
pathway
encod
vacv
discuss
ea
la
shown
neg
regul
nfb
possibl
differ
mechan
ea
suggest
inhibit
activ
nfb
pathway
multipl
point
includ
coval
modif
nfb
inhibit
bind
dna
han
et
al
la
consid
amelior
redox
stress
decreas
nfb
activ
way
kiemer
et
al
petersen
shay
et
al
along
line
la
decreas
hiv
proviru
reactiv
merin
et
al
pand
ramo
contrast
vacv
inhibit
nfb
pathway
sever
gene
product
graham
et
al
therefor
unclear
inhibit
nfb
ea
la
could
inhibit
nfb
activ
prevent
vacv
growth
way
test
inhibitori
effect
ea
la
vacv
growth
use
sever
recombin
vacv
wt
vacv
effect
character
viru
titer
activ
luciferas
cell
differ
embryon
origin
emphas
recombin
virus
use
studi
reveal
similar
growth
properti
vitro
inhibitori
concentr
found
lower
rvacv
wt
vacv
valu
ic
lower
calcul
viru
titer
luciferas
activ
base
ic
ea
effect
hela
g
cell
la
macrophag
rest
cell
valu
ic
ea
rang
virus
la
valu
ic
rang
rvacv
wt
vacv
condit
antivir
assay
two
compound
induc
obviou
cytotox
effect
concentr
use
except
jurkat
cell
ea
seem
toxic
assess
optic
microscopi
howev
base
result
mtt
assay
activ
divid
cell
ea
la
found
rel
nontox
epitheli
fibroblast
cell
line
reveal
inhibitori
effect
macrophag
tcell
line
possibl
differ
redox
milieu
distinct
cell
type
might
respons
differ
effect
two
agent
altern
differ
pattern
express
gst
isoenzym
interact
ea
elimin
ea
cell
may
play
role
gate
tew
ea
la
inhibit
vacv
growth
even
macrophag
stimul
vacv
growth
alreadi
potent
inhibit
inhibit
known
least
partial
mediat
express
ino
product
nitric
oxid
karupiah
et
al
esteban
respect
la
shown
inhibit
lpsinduc
nfband
ino
express
kupffer
cell
raw
macrophag
kiemer
et
al
similarli
observ
addit
decreas
accumul
nitrit
stabl
oxid
product
nitric
oxid
increas
vacv
growth
macrophag
assay
perform
studi
ic
valu
ea
found
rang
cell
use
wt
vacv
strain
wr
la
rang
base
publish
result
ic
valu
cidofovir
prodrug
hexadecyloxyethylest
found
gml
human
embryon
lung
fibroblast
hel
use
vacv
strain
lederl
et
al
anoth
studi
ic
valu
cidofovir
found
vero
cell
human
foreskin
fibroblast
hff
cell
use
two
differ
vacv
strain
wr
becker
et
al
yet
anoth
studi
ic
valu
cidofovir
found
respect
hff
cell
use
vacv
strain
wr
quenel
et
al
howev
difficult
compar
ic
valu
determin
differ
assay
differ
condit
assay
perform
use
moi
h
incub
period
assay
publish
employ
much
lower
moi
usual
day
incub
final
tri
identifi
step
vacv
growth
cycl
inhibit
ea
la
hela
g
cell
neither
ea
la
found
affect
viru
entri
cell
contrast
sever
line
evid
suggest
affect
step
level
viru
late
gene
express
possibl
later
first
use
recombin
virus
express
luciferas
control
two
differ
promot
earlyl
luc
el
late
luc
l
combin
inhibit
vacv
dna
synthesi
arac
virus
use
distinguish
inhibit
process
occur
dna
synthesi
overal
activ
well
protein
level
report
luciferas
express
virus
found
decreas
hela
g
cell
presenc
increas
concentr
ea
la
emphas
uninhibit
absolut
activ
luciferas
express
luc
l
sever
time
higher
express
luc
el
upon
inhibit
vacv
dna
synthesi
arac
level
luciferas
express
either
rvacv
undetect
western
blot
analysi
presenc
arac
activ
luciferas
express
luc
l
strongli
inhibit
activ
luciferas
express
luc
el
decreas
less
absolut
level
sever
time
higher
luc
linfect
sampl
result
confirm
luciferas
express
luc
l
realli
occur
dna
synthesi
luciferas
express
luc
el
occur
also
earlier
dna
synthesi
take
place
howev
neither
ea
la
decreas
luciferas
activ
express
control
earli
promot
suggest
agent
affect
express
earli
gene
second
evid
support
hypothesi
ea
la
inhibit
vacv
late
gene
express
western
blot
analysi
reveal
ea
la
somewhat
affect
level
vacv
protein
chang
overal
pattern
vacv
late
protein
third
quantif
vacv
dna
realtim
pcr
yield
differ
dna
level
due
ea
la
treatment
result
demonstr
inhibitori
action
ea
la
take
place
level
late
gene
express
later
conclus
support
result
time
addit
assay
indic
addit
ea
la
hpi
ie
time
dna
synthesi
accomplish
accord
realtim
pcr
significantli
decreas
viru
growth
character
luciferas
activ
note
concentr
ea
inhibit
vacv
growth
log
hela
g
cell
ea
respect
seem
consider
affect
overal
vacv
protein
level
character
western
blot
analysi
analog
result
could
observ
la
similarli
ic
valu
found
lower
calcul
viru
titer
luciferas
activ
thu
find
might
suggest
ea
la
could
addit
act
step
express
vacv
late
protein
ie
viru
morphogenesi
vacv
morphogenesi
involv
cytoplasm
redox
pathway
constitut
sever
viral
enzym
catalyz
format
intramolecular
disulfid
bond
within
cytoplasm
domain
certain
virion
membran
protein
virion
membran
protein
contain
multipl
cystein
particip
viru
particl
format
matur
viru
entri
cellcel
fusion
ojeda
et
al
townsley
et
al
therefor
expect
ea
la
would
interfer
process
well
ea
deriv
name
amid
suggest
new
lead
structur
nonpeptid
activesitedirect
inhibitor
coronaviru
main
proteas
pro
kaeppler
et
al
proteas
belong
cystein
proteas
famili
member
play
import
role
host
cell
physiolog
patholog
well
variou
stage
life
cycl
virus
parasit
johnston
et
al
vicik
et
al
cystein
proteas
particip
proteolysi
viru
polypeptid
well
core
matur
sever
dna
virus
includ
vacv
alejo
et
al
byrd
et
al
byrd
hrubi
greber
therefor
possibl
ea
could
also
inhibit
vacv
growth
stage
effect
ea
la
would
need
explor
differ
set
experi
addit
antivir
effect
compound
evalu
experi
mice
conclus
demonstr
inhibitori
properti
ea
la
growth
vacv
inhibit
found
occur
level
vacv
late
gene
express
result
suggest
new
direct
develop
drug
effect
poxviru
infect
bring
new
inform
scope
effect
ea
la
